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AbstrACt
Objective To develop and validate multivariable clinical 
diagnostic models to assist distinguishing between type 1 
and type 2 diabetes in adults aged 18–50.
Design Multivariable logistic regression analysis was 
used to develop classification models integrating five 
pre-specified predictor variables, including clinical 
features (age of diagnosis, body mass index) and clinical 
biomarkers (GADA and Islet Antigen 2 islet autoantibodies, 
Type 1 Diabetes Genetic Risk Score), to identify type 1 
diabetes with rapid insulin requirement using data from 
existing cohorts.
setting UK cohorts recruited from primary and secondary 
care.
Participants 1352 (model development) and 582 
(external validation) participants diagnosed with diabetes 
between the age of 18 and 50 years of white European 
origin.
Main outcome measures Type 1 diabetes was defined 
by rapid insulin requirement (within 3 years of diagnosis) 
and severe endogenous insulin deficiency (C-peptide 
<200 pmol/L). Type 2 diabetes was defined by either a lack 
of rapid insulin requirement or, where insulin treated within 
3 years, retained endogenous insulin secretion (C-peptide 
>600 pmol/L at ≥5 years diabetes duration). Model 
performance was assessed using area under the receiver 
operating characteristic curve (ROC AUC), and internal and 
external validation.
results Type 1 diabetes was present in 13% of participants 
in the development cohort. All five predictor variables were 
discriminative and independent predictors of type 1 diabetes 
(p<0.001 for all) with individual ROC AUC ranging from 
0.82 to 0.85. Model performance was high: ROC AUC range 
0.90 (95% CI 0.88 to 0.93) (clinical features only) to 0.97 
(95% CI 0.96 to 0.98) (all predictors) with low prediction 
error. Results were consistent in external validation (clinical 
features and GADA ROC AUC 0.93 (0.90 to 0.96)).
Conclusions Clinical diagnostic models integrating 
clinical features with biomarkers have high accuracy for 
identifying type 1 diabetes with rapid insulin requirement, 
and could assist clinicians and researchers in accurately 
identifying patients with type 1 diabetes.
IntrODuCtIOn
Making the correct diagnosis of type 1 and 
type 2 diabetes is crucial for appropriate 
management, with guidelines for these 
conditions recommending very different 
glucose-lowering treatment and education.1–3 
These differences are predominantly driven 
by the rapid development of severe endog-
enous insulin deficiency in type 1 diabetes.1 
This means that patients with type 1 diabetes 
need rapid insulin treatment and are at 
risk of life-threatening ketoacidosis without 
insulin treatment. They develop a require-
ment for physiological insulin replace-
ment (eg, multiple injections, carbohydrate 
counting, pumps) due to the very high 
glycaemic variability associated with severe 
strengths and limitations of this study
 ► Diabetes type is robustly defined using direct mea-
surement of endogenous insulin secretion, an out-
come closely related to treatment, education and 
monitoring requirements.
 ► A combination of a large development dataset and 
small number of predictors minimises risk of model 
overfitting, a common problem with diagnostic mod-
els of this nature.
 ► Models are robustly internally and externally 
validated.
 ► The cross-sectional nature of the development and 
validation cohorts means that time to insulin was 
self-reported and measurement of model predictors 
was not undertaken at diagnosis: both body mass 
index and islet autoantibody prevalence may change 
over time.
 ► Models have been developed in white European 
populations with young adult onset diabetes: further 
work is required to extend this work to other age 
groups and ethnicities.
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insulin deficiency4 5 and have poor glycaemic response 
to most adjuvant glucose-lowering therapies.6 In contrast, 
patients with type 2 diabetes continue to make substantial 
endogenous insulin even many decades after diagnosis.7 
Glycaemia is therefore usually managed initially with life-
style change or oral agents4 8 and, if insulin treatment is 
needed, a combination of simple insulin regimens and 
adjuvant non-insulin therapies.4 5 8 9
Correctly distinguishing between diabetes subtypes at 
diagnosis is often difficult and misclassification is there-
fore common.10–12 Current guidelines focus on etiopatho-
logical definitions without giving clear criteria for clinical 
use.1 13 In clinical practice, clinical features are predom-
inantly used to determine diabetes subtype but only age 
at diagnosis and body mass index (BMI) have evidence 
for utility at diabetes onset, whereas other features used 
by clinicians such as symptoms at diagnosis, weight loss or 
ketosis do not have an evidence base.14 Increasing obesity 
rates mean that many patients with type 1 diabetes will 
be obese and type 2 diabetes is occurring in the young.15 
Type 1 diabetes has been recently shown to occur at 
similar rates in those aged above and below 30 years.16 
Therefore, simple cut-offs based on age at diagnosis and 
BMI are unlikely to accurately diagnose diabetes type for 
many patients.1 10 Similarly, there is no single diagnostic 
test that can be used to classify diabetes robustly at diag-
nosis. While measurement of islet autoantibodies can 
assist classification, many patients with type 1 diabetes 
are islet autoantibody negative and many patients with 
the clinical phenotype of type 2 diabetes, without rapid 
insulin requirement, are islet autoantibody-positive.17 A 
Type 1 Diabetes Genetic Risk score (T1D GRS) has been 
recently shown to assist diagnosis of diabetes type but this 
provides imperfect discrimination in isolation.18
To classify diabetes, a suitable ‘gold standard’ is neces-
sary. As the key factor driving differences in treatment 
decisions between the two subtypes is the lack of endog-
enous insulin secretion, direct measurement of endog-
enous insulin secretion in long-standing insulin-treated 
diabetes (>3–5 years), using C-peptide, provides a robust 
classification that closely relates to treatment require-
ments19; patients with severe endogenous insulin defi-
ciency (low C-peptide) have the high glucose variability, 
absolute insulin requirement and lack of response to 
non-insulin glucose-lowering therapies that are charac-
teristic of type 1 diabetes, regardless of their clinical char-
acteristics and clinician’s diagnosis.7 11 19–23 However, this 
test may have limited utility at diagnosis, as patients with 
recent onset type 1 diabetes may have retained endoge-
nous insulin secretion.21 24
Clinical prediction models offer a way of combining 
multiple patient features and biomarkers to improve 
accuracy of diagnosis or prognosis. In diabetes, diag-
nostic models combining clinical features are avail-
able to predict the risk of prevalent or incident type 2 
diabetes25 and there is a model to identify monogenic 
forms of diabetes in patients with young-onset diabetes.26 
However, there are no statistical prediction models to 
help distinguish type 1 and type 2 diabetes at diagnosis. 
We therefore aimed to develop and validate multivariable 
clinical diagnostic models that combine clinical features 
and biomarkers to identify type 1 diabetes (defined by 
rapid insulin requirement and severe endogenous insulin 
deficiency) in patients aged between 18 and 50 years at 
diabetes diagnosis.
MethODs
We used logistic regression to model the relationship 
between each of clinical features and biomarkers, and 
type 1 diabetes defined by rapid insulin requirement 
and severe endogenous insulin deficiency (see later). 
We assessed the performance of the models using both 
internal validation and external validation.
study population: development cohort
For model development, participants were identified from 
Exeter, UK-based cohorts.27–30 These cohorts were partic-
ipants with clinically diagnosed diabetes recruited from 
primary and secondary care. Summaries of the cohorts 
including recruitment and data collection methods are 
shown in online supplementary table 1.
Participants were eligible for the study (model devel-
opment or validation) if they had a clinical diagnosis 
of diabetes between the ages of 18 and 50 years. Partic-
ipants with known secondary or monogenic diabetes,31 
or a known disorder of the exocrine pancreas,32 were 
excluded. All participants included in this study were of 
white European origin.
study population: external validation cohort
Participants meeting the study inclusion criteria were 
identified in the Young Diabetes in Oxford (YDX) study.33 
YDX is a cross-sectional study of participants diagnosed 
with diabetes (of any type) up to the age of 45 years, 
recruited from primary and secondary care in the Thames 
Valley region, UK. Participants with known secondary, 
pancreatic or monogenic diabetes were excluded.
Model outcome: type 1 and type 2 diabetes definition
Type of diabetes was defined by the presence or absence 
of rapid insulin requirement and severe endogenous 
insulin deficiency after a diagnosis of diabetes, as follows:
Type 1 diabetes: Insulin treatment within ≤3 years 
of diabetes diagnosis and severe insulin deficiency 
(non-fasting C-peptide <200 pmol/L).21
Type 2 diabetes: Either (1) no insulin requirement for 
3 years from diabetes diagnosis or (2) where insulin was 
started within 3 years of diagnosis, substantial retained 
endogenous insulin secretion (C-peptide >600 pmol/L) 
at ≥5 years diabetes duration.
Cohort participants not meeting the above criteria or 
with insufficient information were excluded from anal-
ysis, as type of diabetes and rapid insulin requirement 
could not be robustly defined.
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Model predictors
Five pre-specified predictor variables were assessed, based 
on prior evidence and availability: age at diagnosis,14 
BMI,14 GADA (Glutamic acid decarboxylase autoanti-
body) and IA-2A (Islet antigen-2 autoantibody),17 34 and 
a T1D GRS.18
Assessment of clinical features
At study recruitment visit, clinical history including time 
to insulin and age at diagnosis were self-reported by 
participants in an interview with a research nurse. Height 
and weight were measured for calculation of BMI.
Laboratory measurement
C-peptide
In the development cohort, C-peptide was measured on 
stored EDTA taken at study visits (non-fasting random,35 
fasting or at 90 min in a post-mixed-meal tolerance test 
(majority 87% non-fasting)). With specific additional 
consent, C-peptide was also measured on post-recruit-
ment non-fasting EDTA (Ethylenediaminetetraacetic 
acid) samples collected as part of routine clinical care. 
Fasting C-peptide values were multiplied by 2.5 to 
non-fasting equivalent.21 The median C-peptide value 
was used where more than one eligible C-peptide value 
was available (62% of participants requiring this measure 
for outcome definition). C-peptide was measured using 
an electrochemiluminescence immunoassay on a Roche 
Diagnostics E170 analyser (Roche, Mannheim, Germany) 
by the Academic Department of Blood Sciences at the 
Royal Devon and Exeter Hospital. In the external vali-
dation cohort, C-peptide measurement was performed 
in the Biochemistry Laboratory of the Oxford University 
Hospitals NHS (National Health Service) Trust using a 
chemiluminescence immunoassay on an ADVIA Centaur 
analyser (Siemens Healthcare Diagnostics).
Islet autoantibodies
In the development cohort, GADA and IA-2A were 
measured on EDTA taken at recruitment or obtained 
from local laboratory records. Both islet autoantibodies 
were measured using the RSR ELISA assays (RSR Ltd, 
Cardiff, UK) on the Dynex DS2 ELISA Robot (Dynex 
Technologics, Worthing, UK) by the Academic Depart-
ment of Blood Sciences at the Royal Devon and Exeter 
Hospital. The department participates in the Interna-
tional Autoantibody Standardisation Programme. The 
cut-off for positivity for GADA was ≥11 units/mL and 
IA-2A was ≥15 units/mL, based on the 97.5th percentile 
of 1559 controls without diabetes.34
In the external validation cohort, GADA was measured 
by a radioimmunoassay using 35S-labelled full-length 
GAD65 by the Department of Clinical Science, University 
of Bristol, Bristol, UK. Results were expressed in WHO 
units per millilitre derived from a standard curve cali-
brated from international reference material (National 
Institute for Biological Standards and Control code 
97/550). The cut-off for positivity for GADA was 13 WHO 
Units/mL initially, using a local assay (samples measured 
n=218, Diabetes Antibody Standardisation Program 
(DASP) 2010 sensitivity 88% and specficity i93%) and 
changed to 33 DK units/mL later in the study (standard 
assay, DASP2010 sensitivity 80%, specificity 97%).
Type 1 diabetes genetic risk score
The T1D GRS was calculated on the development cohort 
as previously described.18 In brief, T1D GRS consists of 30 
common type 1 diabetes genetic variants (single nucleo-
tide polymorphisms (SNPs)) from HLA (Human Leuko-
cyte Antigen) and non-HLA loci; each variant is weighted 
by its effect size on type 1 diabetes risk from previously 
published literature, with weights for DR3/DR4-DQ8 
assigned based on imputed haplotypes (online supple-
mentary table 2). All SNPs had an INFO (Information 
content metric)>0.8. The combined score represents an 
individual’s genetic susceptibility to type 1 diabetes. T1D 
GRS calculation was not performed if genotyping results 
were missing for either of the two alleles with the greatest 
weighting (DR3/DR4-DQ8 or HLA_DRB1_15) or if more 
than two of any other SNPs were missing. For ease of clin-
ical interpretation, the score is presented in this article as 
the score and centile position of the distribution in the 
Wellcome Trust Case Control Consortium type 1 diabetes 
population.36
statistical analysis
Model development
We used logistic regression analysis to develop the models. 
Models were developed on a complete case basis.
Age at diagnosis, BMI and T1D GRS were modelled as 
continuous variables and transformations used to ensure 
linearity on the logit scale37 (online supplementary figure 
1AB). GADA and IA-2A were both dichotomised into 
negative or positive based on the cut-off for positivity in 
line with how the results are reported clinically.2 Sample 
sizes were checked using both minimal events per vari-
able (EPV) criteria (≥10)38 and square root of the mean 
squared prediction error39 and were considered sufficient 
for reliable diagnostic modelling.
Models were built and validated in four stages, this 
staged development sequence was selected in order of 
clinical availability of the predictors and, as some partic-
ipants had missing diagnostic test data, to maximise the 
sample size at each stage: (1) model including only clin-
ical features (age at diagnosis and BMI); (2) addition of 
GADA to the linear predictor from model 1; (3) addition 
of both GADA and IA-2A to the linear predictor from 
model 1 and (4) addition of T1D GRS to model three 
linear predictor.
Evaluation of model performance: internal validation
Three internal validation techniques were used to assess 
the discrimination and calibration performance of the 
models: (1) directly using the data used to develop the 
model (apparent validation, area under the receiver oper-
ating characteristic curve (ROC AUC)); (2) Jack-knife 
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cross-validation and (3) bootstrapping (with replacement 
method)37
Evaluation of model performance: external validation
Performances of model 1 (clinical features) and model 
2 (clinical features+GADA) were evaluated in the YDX 
study cohort. We were unable to externally evaluate 
models 3 and 4 as IA-2A autoantibodies and T1D GRS 
were not available in the YDX study.
Model comparisons
Four nested replica models were built on the subset of 
participants with complete data on all predictor variables 
(n=943). The predictive information of each additional 
predictor on the model performance was assessed using 
the Unitless Index of Adequacy,37 log likelihood ratio 
test,37 Net Reclassification Improvement and Integrated 
Discrimination Improvement.40
sensitivity analysis
Model development of all four models was repeated on 
943 participants with complete data. To assess perfor-
mance of biomarker models in those difficult to classify 
on clinical features alone, AUC ROC was repeated for 
each model in participants with intermediate age of diag-
nosis (range 25–35 years (inclusive)) and BMI (range 
25–35 kg/m2 (inclusive)).
All statistical analyses were performed using STATA 
V.15, STATA Corp, Texas, USA (unless otherwise stated).
Patient involvement
Patients with diabetes were involved in prioritising 
the research question and development of the orig-
inal funding application. This study did not involve 
the collection of primary data, but this research was 
reviewed and access to data approved by the Penin-
sula Research Bank Lay steering committee, who also 
contributed to the design and development of the 
source cohort studies.
resuLts
In all, 1352 (type 1 diabetes n=179) participants met 
analysis inclusion criteria for the clinical features model 
with 943 participants having all predictor variables 
measured. A flow diagram describing the flow of partic-
ipants through the study is shown in online supple-
mentary figure 2. Only 37 (2.7% of the cohort) had an 
undefinable outcome due to intermediate C-peptide 
levels (200–600 pmol/L when insulin-treated diabetes 
within 3 years of diagnosis). The remaining exclu-
sions were due to either missing data or short duration 
of diabetes. The characteristics and type 1 diabetes 
outcome prevalence of the included participants were 
similar in all four development samples (online supple-
mentary table 3). There were no clinically relevant 
differences in the characteristics of the participants 
who were excluded from the fourth model development 
stage (n=409) (online supplementary table 4). Islet 
autoantibodies and C-peptide were measured at median 
13 years and 16 years post-diagnosis, respectively.
Clinical features or biomarkers in isolation overlap 
substantially between diabetes types
Participants with type 1 diabetes and rapid insulin 
requirement were diagnosed younger compared to the 
participants with type 2 diabetes (median 27 vs 44 years, 
p < 0.001) and had a lower BMI (median 26 vs 34 kg/
m2, p < 0.001). Positive autoantibodies (GADA, IA-2A 
or both) were more common in the participants with 
type 1 diabetes (71% of participants with type 1 diabetes 
vs 5% of participants with type 2 diabetes, p < 0.001). 
Patients with type 1 diabetes had a higher T1D GRS 
(median 0.27 vs 0.23 (equivalent to 40th and 4th centiles 
of the Wellcome Trust Case Control Consortium popu-
lation with type 1 diabetes,36 p < 0.001). These features 
overlapped substantially between participants meeting 
criteria for type 1 and type 2 diabetes (figure 1A–D) 
with AUC ROC for these features in isolation: 0.82 (age 
at diagnosis), 0.83 (BMI), 0.83 (islet autoantibodies) 
and 0.85 (T1D GRS).
Combining clinical features using a diagnostic model 
improves model discrimination
In model 1, age at diagnosis and BMI were both signifi-
cant independent predictors of type 1 diabetes, with the 
odds of having type 1 diabetes increasing with younger 
age at diagnosis and lower BMI. Combined, these features 
provided excellent discrimination (ROC AUC=0.904, 
perfect test=1) (figure 2A), with low probabilities 
capturing the majority of participants with type 2 diabetes 
and type 1 diabetes being very unlikely (figure 2B; sensi-
tivity, specificity, and positive and negative predictive 
values at various probability cut-offs are reported in 
table 1). In successive models adding in GADA (model 2 
(figure 2C and D)), then IA-2A (model 3 (figure 2E and 
F)) and then T1D GRS (model 4 (figure 2G and H)), the 
addition of each predictor to the previous model resulted 
in significant improvements in discrimination (online 
supplementary table 5) and model fit (online supplemen-
tary tables 67). In sensitivity analysis, results were similar 
when restricting all models to only the 943 participants 
with complete data on all predictor variables (online 
supplementary table 8).
In further sensitivity analysis restricting analysis to those 
most difficult to classify on clinical features alone due to 
both intermediate BMI (range 25–35 kg/m2 (inclusive)) 
and age of diagnosis (range 25–35 years (inclusive)), 
model performance remained high for models incorpo-
rating biomarker measurement (clinical features+islet 
autoantibodies AUC ROC 0.89, clinical features+islet 
autoantibodies+T1D GRS AUC ROC 0.95) (online 
supplementary table 9). This compares to AUC ROC of 
0.72 for GADA and IA-2A measurement alone, and 0.89 
for T1D GRS measurement alone in this subpopulation 
(n=71).
copyright.
 o
n
 N
ovem
ber 13, 2019 at University of Exeter. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031586 on 26 September 2019. Downloaded from 
5Lynam A, et al. BMJ Open 2019;9:e031586. doi:10.1136/bmjopen-2019-031586
Open access
Figure 1 Density plots for (A) age at diagnosis, (B) BMI and (D) T1D GRS. Stacked bar chart (C) showing percentages of 
participants (total n=943 (stage 4 model development sample)) by actual type 1 diabetes outcome and GADA/IA-2A status. 
Dashed line shows the distribution for T2D (n=815), solid line shows the distribution for T1D (n=128) of participants included in 
the stage 4 model development. BMI, body mass index; T1D GRS, type 1 diabetes Genetic Risk Score; T2D, type 2 diabetes.
Internal validation suggests robust model performance
Results of the internal validation bootstrap (online 
supplementary table 5) indicate good model discrim-
ination, with very similar model performance in boot-
strapped samples (near identical ROC AUC for all models 
(max decrease=0.0018)), high calibration indicating the 
predicted probabilities closely fit the observed probabili-
ties (calibration slope range 0.98–1.00 (0.9–1.1 is indica-
tive of good calibration)), and very low levels of optimism 
suggesting little error due to overfitting.
Model performance remains high in an external validation 
cohort with different characteristics
582 participants in the YDX study met criteria for external 
validation (Supplementary Figure 3). Compared to the 
participants in the Exeter model development cohort, 
the participants in the YDX study were younger at diag-
nosis (consistent with the narrower age range in YDX 
(18–45 years) (median 37 years vs 43 years, p < 0.001)), 
had a lower BMI (median 31 kg/m2 vs 33 kg/m2, p < 
0.001), had a higher percentage of GADA (20% vs 12%, 
p < 0.001) and a higher prevalence of type 1 diabetes by 
study definition (22% vs 14%, p < 0.001) (see Supplemen-
tary Table 10 for participant characteristics).
There was a small decrease in performance of the 
model 1 (clinical features) and model 2 (clinical 
features and GADA) when they were applied to the 
external validation samples but both still showed high 
levels of discrimination despite differences in the two 
cohorts (ROC AUC=0.865 and 0.930 for models 1 
(figure 3A, B and C) and 2 (figure 3D, E and F), respec-
tively (online supplementary table 11). Both models 
slightly over estimated type 1 diabetes prevalence but 
there was no evidence of miscalibration (figure 3B 
and E, online supplementary table 11). Sensitivity and 
specificity in the validation cohort are shown in online 
supplementary table 12.
Participants with high model probability type 1 diabetes but 
type 2 diabetes outcome have the characteristics of type 1 
diabetes but took > 3 years to commence insulin therapy
Online supplementary table 13 shows the characteristics 
of 12 participants in the external validation cohort with 
>80% model type 1 diabetes probability, but an actual 
model outcome of type 2 diabetes. These participants had 
the clinical characteristics associated with type 1 diabetes 
with GADA positivity and low C-peptide in the majority 
of cases (median C-peptide 120 pmol/L). However, the 
time to insulin was >3 years in GADA-positive cases, 
suggesting slow onset autoimmune diabetes. In contrast, 
the six participants who had a low model type 1 diabetes 
probability (<16%) but an actual model outcome of type 
1 diabetes (online supplementary table 14) had features 
associated with type 2 diabetes.
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Figure 2 Development sample validation results. Plots are the results from the validation of the models. First row (A and B): 
clinical features logistic regression model (n=1315). Second row (C and D): clinical features+GADA logistic regression model 
(n=1036). Third row (E and F): clinical features+GADA + IA-2A logistic regression model (n=1025). Fourth row (G and H): 
clinical features+GADA + IA-2A+T1D GRS logistic regression model (n=943). Plots (A), (C), (E), & (G) are ROC curves showing 
discrimination ability of the models. Plots (B), (D), (F) and (H) are boxplots of fitted model probabilities grouped by actual 
diabetes outcome. ROC, receiver operating characteristic; T1D GRS, Type 1 Diabetes Genetic Risk Score.
Online calculator
The four models have been incorporated into an online 
calculator (beta version available at https://www. diabetes-
genes. org/ t1dt2d- prediction- model/). An additional four 
models with different combinations of the five predictor 
variables were also developed for the online calculator, to 
allow every combination of clinical features plus the other 
biomarkers as optional. As expected, ROC AUC and predic-
tion error results for these four additional models were 
intermediate between the basic clinical features model and 
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Table 1 Model performance at different cut-offs for all four logistic regression models (development cohort). Positive and 
negative predictive values relate to type 1 diabetes NPV, negative predictive value; PPV, positive predictive value
Clinical features (n=1352)
Probability (%) cut-off for classifying type 1 diabetes
10 30 50 70 90 12 (Youden’s 
Index)
Sensitivity/specificity (%) 85/79 64/95 49/98 35/99 15/100 83/83
Accuracy (%) 80 90 91 90 89 83
PPV (%) 38 64 79 83 90 42
NPV (%) 97 95 93 91 89 97
Clinical features+GADA (n=1036)
Probability (%) cut-off for classifying type 1 diabetes
10 30 50 70 90 16 (Youden’s 
Index)
Sensitivity/specificity (%) 90/88 80/96 66/97 52/99 31/100 86/92
Accuracy (%) 89 94 93 92 90 92
PPV (%) 55 75 80 85 92 64
NPV (%) 98 97 95 93 90 98
Clinical features+GADA + IA-2A (n=1025)
Probability (%) cut-off for classifying type 1 diabetes
10 30 50 70 90 12 (Youden’s 
Index)
Sensitivity/specificity (%) 91/91 80/96 69/98 57/99 37/100 90/92
Accuracy (%) 91 94 94 93 92 92
PPV (%) 59 75 81 85 92 62
NPV (%) 99 97 96 94 92 98
Clinical features+GADA + IA-2A+T1D GRS (n=943)
Probability (%) cut-off for classifying type 1 diabetes
10 30 50 70 90 14 (Youden’s 
Index)
Sensitivity/specificity (%) 92/90 84/96 74/98 63/99 41/100 91/93
Accuracy (%) 90 95 94 94 92 93
PPV (%) 59 78 83 88 93 67
NPV (%) 99 98 96 94 92 99
Accuracy = (true positives + true negatives)/total number of participants. PPV = [(sensitivity × prevalence)/[(sensitivity × prevalence) + ([1 –
specificity] × [1−prevalence])]. NPV = [specificity × (1 − prevalence)]/[(specificity × [1 − prevalence]) + ([1 − sensitivity] × prevalence)]. Youden’s Index 
− best trade-off between sensitivity and specificity (sensitivity+specificity – 1).
NPV, negative predictive value; PPV, positive predictive.
the full model with all features (see online supplementary 
table 15).
Online supplementary tables 16–23 inclusive show the 
β-coefficients and ORs for all models. The regression 
equations for the online calculator are shown in online 
supplementary table 24.
DIsCussIOn
We have developed, evaluated and validated clinical diag-
nostic models combining age at diagnosis, BMI, GADA, 
IA-2 and T1D GRS to provide estimates of a patient’s risk 
of having type 1 diabetes requiring rapid insulin therapy 
from diagnosis. These models show high performance 
and could potentially assist classification of diabetes in 
clinical practice and provide a tool for evidence-based 
classification in research cohorts.
Model performance was optimised in the model 
combining all five predictors (ROC AUC 0.97). However, 
all models performed well with ROC AUC >0.9 and low 
cross-validated prediction errors in development. The 
results of the external validation provide additional confi-
dence in model performance. This was undertaken in a 
distinct dataset with different type 1 diabetes prevalence 
and biochemical assays.
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Figure 3 External validation results. Plots on the first row (a, b, c) are the results from the external validation of the clinical 
features logistic regression model applied to participants in the YDX study (n=582). The second row of plots (d, e and f) are 
the results from the external validation of the clinical features+GADA logistic regression model applied to participants in the 
YDX study (n=549). Plots (a) and (d) are ROC curves showing discrimination ability of the models, dashed line represents the 
reference line. Plots (b) and (e) are calibration plots. Plots (c) and (f) are boxplots of fitted model probabilities grouped by actual 
diabetes outcome. ROC, receiver operating characteristic; YDX, Young Diabetes in Oxford.
This is the first study developing clinical diagnostic 
models for classification of type 1 and 2 diabetes. Key 
strengths of this study include our systematic approach 
to model development including robust internal and 
external validation.41 Our staged approach to model 
development means that we have maximised the infor-
mation gained from each predictor. Our model is 
parsimonious, we have used only five predictors previ-
ously shown to be associated with type 1 diabetes. This, 
in combination with large datasets, mean we have a 
high number of EPV and very low risk of overfitting, 
a common problem with diagnostic models of this 
nature. Our use of predominantly population-based 
cohorts recruited largely from a primary care setting 
(for model development) means our results are likely 
to reflect true associations in patients seen in clinical 
practice. The overall prevalence of study defined type 
1 diabetes of 13% in our development dataset is close 
to the 11% reported type 1 diabetes prevalence at diag-
nosis in a UK population aged 20–50 years.42
A limitation of our study is the cross-sectional 
nature of our cohorts meaning that age at diagnosis 
and time to insulin were self-reported at a single 
visit. Insulin commencement was also based on clin-
ical decision-making rather than a trial protocol. BMI 
and antibodies were measured at median 13 years 
after diagnosis. BMI, and GAD and IA-2A antibodies 
change modestly over time in adult onset diabetes, with 
previous research suggesting an approximately 18% 
lower combined GADA and IA-2A prevalence after 13.5 
years diabetes duration in this age group,43 and BMI 
having higher discrimination for diabetes classification 
when measured at diagnosis.44 The potential impact on 
the results of BMI and islet autoantibodies having been 
measured some years post-diagnosis is that the predic-
tions may be under-estimated. The lack of information 
at diagnosis also meant we were unable to assess whether 
other features available at diagnosis may assist classifica-
tion, such as presentation glycaemia, ketosis or weight 
loss. A prospective study to validate these models, and 
assess whether other features may assist classification 
is therefore ongoing (https:// clinicaltrials. gov/ ct2/ 
show/ NCT03737799).
A further limitation is that this model has been devel-
oped and tested in a white European population with 
young onset diabetes, extension of this work to non-white 
populations and older age groups is therefore a priority 
for future research.
These models have the potential to help robustly clas-
sify diabetes in research cohorts, and may have particular 
utility where genetic but not antibody data is available, 
a common situation in many biobanks. They may also 
assist clinical decision-making, with the important caveats 
that this evidence can only be applied to patients aged 
18–50 years, of white ethnicity, and that these models 
are intended to act as a decision aid in conjunction with 
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other information which a clinician may use to inform 
treatment decisions (eg, severity of hyperglycaemia): 
they do not replace expert clinical opinion. A web-based 
calculator and smartphone app could be used to display 
the estimate of the patient’s probability of having type 1 
diabetes based on the predictor variable values entered. 
The models can be used with age of diagnosis and BMI as 
a minimum; users will then have a choice to add results 
of GADA, IA-2A and T1D GRS in any combination. This 
could therefore be used by clinicians as a triage-based 
approach to diabetes subtype diagnosis. For example, 
probabilities calculated on clinical features could be used 
as the basis for antibody testing, or the additional value 
likely to be gained from antibody or genetic testing could 
be assessed by inputting dummy results into the model. We 
propose providing the continuous probability outcome of 
the models rather than giving a threshold. This is because 
the decision made on whether to commence insulin for a 
given probability of type 1 diabetes will vary enormously 
due to other factors. For example, temporary insulin 
treatment may be appropriate regardless of likely clas-
sification where hyperglycaemia is severe, and in some 
circumstances it may be appropriate to trial oral therapy 
even where type 1 diabetes has a high probability, for 
example where a person’s occupation would be affected 
by insulin treatment and they can be carefully monitored 
for glycaemic deterioration.
In conclusion, clinical diagnostic models integrating 
clinical features with biomarkers have high accuracy for 
identifying type 1 diabetes with rapid insulin requirement 
in white participants aged 18–50 years at diabetes diag-
nosis, and may assist clinicians in identifying patients with 
type 1 diabetes in clinical practice.
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